CGAS and metabolic dysfunction-associated steatotic liver disease: Furthermore, scRNA‐Seq or spatial‐omics analyses to examine hepatocyte‐specific cGAS/ALDH2 signaling warrant further investigation in both healthy and MASLD patient samples.